Cotrimoxazole 800Mg Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 80 mg trimethoprim / 400 mg sulfamethoxazole
Reference Brands: Bactrim, Septra(US & EU)
Category:
Transplant
Cotrimoxazole tablets combine trimethoprim and sulfamethoxazole to inhibit bacterial folic acid synthesis, preventing DNA replication. It effectively treats urinary, respiratory, and skin infections. Benefits include broad-spectrum antibacterial activity, symptom relief, decreased infection transmission, and support for effectively managing urinary, respiratory, and skin bacterial infections.
Cotrimoxazole 800mg tablets is available in Tablets
and strengths such as 80 mg trimethoprim / 400 mg sulfamethoxazole.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cotrimoxazole 800mg tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cotrimoxazole 800mg tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cotrimoxazole tablets, marketed as Bactrim and Septra, are approved in the US by the FDA and in the EU via EMA for treating bacterial infections including urinary tract, respiratory, and skin infections. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews clinical trial and quality data, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional requirements supports timely approval, safe use, and worldwide availability of cotrimoxazole tablets, ensuring effective antibacterial therapy for patients across the globe.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing